Tag: MAPS - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Post published:January 5, 2023
Post category:Announcements

Read more about the article MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Post published:November 17, 2022
Post category:News Press Release

Read more about the article Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Post published:December 2, 2020
Post category:Press Release

Read more about the article MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

Post published:October 27, 2020
Post category:Press Release

Read more about the article Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

Post published:August 20, 2020
Post category:Press Release

Read more about the article MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

Post published:June 21, 2020
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.